Clinical Trials Logo

Lung Diseases, Obstructive clinical trials

View clinical trials related to Lung Diseases, Obstructive.

Filter by:

NCT ID: NCT00380796 Completed - COPD Clinical Trials

A Long-term Safety Study of Infliximab in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).

Start date: April 2006
Phase: Phase 4
Study type: Observational

The purpose of this long-term observational study is designed to collect additional information on incidence of cancer and cause of death among patients who have participated in clinical trials of infliximab in the treatment of COPD. Patients must have received at least 1 dose of study agent (ie, placebo or infliximab) in the primary studies to be eligible for participation in this long-term follow-up study. Information on deaths and cancers will be collected twice yearly for a period of 5 years from each patient's last safety visit in the primary study.

NCT ID: NCT00379730 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Prednisolone Novel Endpoint Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Start date: March 21, 2006
Phase: Phase 1
Study type: Interventional

Prednisolone will be used as a model medication to identify new clinical outcomes for future evaluation of new therapies in short-term studies (up to 4 weeks) in patients with Chronic Obstructive Pulmonary Disease (COPD).

NCT ID: NCT00379028 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

Airway Clearance Study

Start date: September 2006
Phase: Phase 4
Study type: Interventional

The purpose of the study is to evaluate how the airways in COPD patients, compared to healthy volunteers, absorb steroid drugs from Symbicort Turbuhaler and Seretide Diskus. The blood concentrations of the steroids will be used as surrogate marker.

NCT ID: NCT00372112 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

A Study To Assess The Safety And Tolerability Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Start date: November 3, 2006
Phase: Phase 2
Study type: Interventional

The compound GW642444 has previously been found to be well tolerated with no significant side effects in subjects with asthma and healthy volunteers. This study will assess the safety and tolerability of GW642444 in subjects with COPD in order to obtain information to support dosing in a broader population of subjects with COPD

NCT ID: NCT00363896 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease (COPD)

A Trial Assessing LAS34273 in Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)

Start date: August 2006
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy and safety of LAS 34273 compared to placebo in patients with moderate to severe COPD during one year of treatment.

NCT ID: NCT00361959 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

SERETIDE 50/500mcg Versus Tiotropium Bromide On Exacerbation Rates In Severe Chronic Obstructive Pulmonary Disease

Start date: June 2003
Phase: Phase 4
Study type: Interventional

This is a comparator study to assess the relative efficacy of the combination product fluticasone propionate/salmeterol 50/500 and tiotropium bromide on the rate of exacerbations of chronic obstructive pulmonary disease (COPD) over a two year study interval.

NCT ID: NCT00358436 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease (COPD)

Efficacy and Safety of LAS 34273 in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease(COPD)

Start date: July 2006
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy and safety of LAS 34273 compared to placebo in patients with moderate to severe COPD during one year of treatment.

NCT ID: NCT00358358 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Chronic Obstructive Pulmonary Disease Endpoints Study

Start date: March 2006
Phase: Phase 4
Study type: Interventional

This study will last for approximately 14 weeks and will involve 5 visits. The study is being carried out to look at different ways of measuring the effect of drug treatment on COPD. COPD is a respiratory disease which can affect your breathing and daily life. Symptoms of COPD can include breathlessness, cough, and wheeze. COPD varies enormously from patient to patient. The effects of drug treatment are usually measured by conducting lung function tests (breathing tests) using a machine called a spirometer but this does not always provide a complete picture of how well your COPD is responding. In this study we therefore want to look at new and more sensitive ways of measuring COPD. The results of this research will help in the assessment of new drugs for COPD in the future.

NCT ID: NCT00355732 Completed - Respiratory Failure Clinical Trials

Chronic Obstructive Pulmonary Disease and Weaning From Mechanical Ventilation in Difficult to Wean Patients

Start date: n/a
Phase: Phase 4
Study type: Interventional

To evaluate and compare two methods of weaning from mechanical ventilation in patients with chronic obstructive pulmonary disease (COPD) where the extubation failed.

NCT ID: NCT00355342 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Bone Mineral Density Study In Patients With Chronic Obstructive Pulmonary Disease. DISKUS® Inhaler is a Trademark of the GSK Group of Companies.

Start date: April 28, 2004
Phase: Phase 4
Study type: Interventional

This study will last up to 3 years. You will visit the clinic up to 14 times. Certain visits will include lung function tests and scans of your bones. The purpose of this study is to determine the effect of the steroid component of an inhaled product on bone mineral density in patients with Chronic Obstructive Pulmonary Disease (COPD).